Skip to main content
SpringerLink
Log in

Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture

  • Chapter
  • First Online:
Vertebral Compression Fractures in Osteoporotic and Pathologic Bone

  • 667 Accesses

Abstract

Vertebral fractures are the most common type of osteoporotic fracture and pose considerable morbidity and mortality along with a profound socioeconomic burden. Recognition of this often silent medical diagnosis is crucial to ensure appropriate treatment of osteoporosis and fracture prevention. This chapter seeks to inform the reader on the evaluation and medical management of vertebral osteoporosis with review of the epidemiology, risk factors, socioeconomic impact, and diagnostic approach to this condition. Furthermore, we discuss key elements in risk factor modification and treatment considerations for vertebral osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Marwick C. Consensus panel considers osteoporosis. JAMA. 2000;283:2093–5.

    Article  CAS  PubMed  Google Scholar 

  2. Longo UG, Loppini M, Denaro L, Maffulli N, Denaro V. Osteoporotic vertebral fractures: current concepts of conservative care. Br Med Bull. 2012;102:171–89.

    Article  PubMed  Google Scholar 

  3. Bouxsein M, Genant H. International Osteoporosis Foundation. Vertebral Fracture Audit. www.iofbonehealth.org. 2010.

  4. Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G. Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int. 2017;28(5):1531–42.

    Article  CAS  PubMed  Google Scholar 

  5. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C, IOF Working Group on Epidemiology and Quality of Life. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–56. Epub 2012 Mar 15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fink HA, Milavetz DL, Palermo L, et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res. 2005;20(7):1216–22.

    Article  PubMed  Google Scholar 

  7. Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000;11:577–82.

    Article  CAS  PubMed  Google Scholar 

  8. O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ, the European Vertebral Osteoporosis Study Group. The prevalence of vertebral deformity in European men and women: the european vertebral osteoporosis study. J Bone Miner Res. 1996;11:1010–8.

    Article  PubMed  Google Scholar 

  9. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. Clinician’s guide to prevention and treatment of osteoporosis. Position Paper. Osteoporos Int. 2014;25:2359. https://doi.org/10.1007/s00198-014-2794-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin N Am. 2005;34:1015–30.

    Article  CAS  Google Scholar 

  11. Office of the Surgeon General (US). Bone Health and Osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from https://www.ncbi.nlm.nih.gov/books/NBK45513/. 2004.

  12. Day JC. Population projections of the United States by age, sex, race, and hispanic origin: 1995 to 2050. Washington, D.C.: U.S. Government Printing Office; 1996.

    Google Scholar 

  13. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.

    Article  PubMed  Google Scholar 

  14. The International Society for Clinical Densitometry (ISCD). Official Positions 2015 ISCD Combined (US), Middletown. Available from www.ISCD.org.

  15. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases. University of Sheffield, UK. 2007.

    Google Scholar 

  16. Lenchik L, Rogers LF, Selmas PD, Genant HK. Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. Am J Roentgenol. 2004;183(4):949–58.

    Article  Google Scholar 

  17. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral incidence in women. Ann Intern Med. 1991;114(11):919–23.

    Article  CAS  PubMed  Google Scholar 

  18. Kanis JA, Johnell O, Oden A, Johansson H, McClaskey EV. FRAX™ and the assessment of fracture probability in men and women for the UK. Osteoporos Int. 2008;19:385–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kanis JA, Oden A, Johnell O, et al. The Use of Clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–46.

    Article  CAS  PubMed  Google Scholar 

  20. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA manufacturers for FRAX ® Implementation. Available at http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf.

  21. Gillespie LD, Gillespie WJ, Robertson MC, et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev. 2003;(4):CD000340.

    Google Scholar 

  22. Granacher U, Gollhofer A, HortoBágyi T, Kressig RW, Muehlbauer T. The importance of trunk muscle strength for balance, functional performance and fall prevention in seniors: a systematic review. Sports Med. 2013;43(7):627–41.

    Article  PubMed  Google Scholar 

  23. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008;56(12):2234–43.

    Article  PubMed  Google Scholar 

  24. Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis. J Am Med Dir Assoc. 2012;13(2):188.e13–21.

    Article  Google Scholar 

  25. Berg WP, Alessio HM, Mills EM, et al. Circumstances and consequences of falls in independent community-dwelling older adults. Age Ageing. 1997;26:261–8.

    Article  CAS  PubMed  Google Scholar 

  26. Wyman JF, Croghan CF, Nachreiner NM, et al. Effectiveness of education and individualized counseling in reducing environmental hazards in the homes of community-dwelling older women. J Am Geriatr Soc. 2007;55:1548–56.

    Article  PubMed  Google Scholar 

  27. Stevens JA, Baldwin GT, Ballesteros MF, Noonan RK, Sleet DA. An older adult falls research agenda from a public health perspective. Clin Geriatr Med. 2010;26:767–79.

    Article  PubMed  Google Scholar 

  28. Rubenstein LZ, Josephson KR, Robbins AS. Falls in the nursing home. Ann Intern Med. 1994;121:442–51.

    Article  CAS  PubMed  Google Scholar 

  29. National Osteoporosis Foundation (NOF). Health Professional’s guide to rehabilitation of the patient with osteoporosis. Washington, D.C.: National Osteoporosis Foundation; 2003.

    Google Scholar 

  30. Osteoporosis – Prevention, diagnosis and treatment: a systematic review [Internet]. Swedish Council on Health Technology Assessment. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2003. SBU Yellow Report No. 165/1+2.

    Google Scholar 

  31. Waugh EJ, Lam MA, Hawker GA, McGowan J, Papaioannou A, Am C, et al. Risk factors for low bone mass in healthy 40–60 year old women: a systematic review of the literature. Osteoporos Int. 2009;20:1–21.

    Article  CAS  PubMed  Google Scholar 

  32. Maurel DB, Boisseau N, Benhamou CL, Jaffre C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int. 2012;23(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  33. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370–8.

    Article  CAS  PubMed  Google Scholar 

  34. Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or Vitamin D supplementation and fracture incidence in community-dwelling older adults; a systematic review and meta-analysis. JAMA. 2017;318(24):2466–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Institute of Medicine (US) Committee to review dietary reference intakes for Vitamin D and calcium. In: Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary reference intakes for calcium and vitamin D. Washington, D.C.: National Academies Press (US); 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070.

  36. Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporosis Int. 2013;24(2):567–80.

    Article  CAS  Google Scholar 

  37. Reid IR, Bolland MJ. Calcium supplements: bad for the heart? Heart. 2012;98(12):895–6.

    Article  CAS  PubMed  Google Scholar 

  38. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;19, 342

    Google Scholar 

  39. Moyer VA, U.S. Preventative Services Task Force. Vitamin D and calcium supplements to prevent fractures in adults: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med. 2013;158(9):691–6.

    PubMed  Google Scholar 

  40. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, Park Y. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med. 2013;173(8):639–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Looker SC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared to 2000-2004. Am J Clin Nutr. 2008;88(6):1519–27.

    Article  CAS  PubMed  Google Scholar 

  42. Wortsman J, Matsukoa LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–3.

    Article  CAS  PubMed  Google Scholar 

  43. Khaw KT, Stewart AW, Waayer D, Lawes CMM, Toop L, Camargo CA Jr, Scragg R. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol. 2017;5(6):438–47.

    Article  CAS  PubMed  Google Scholar 

  44. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–22.

    Article  CAS  PubMed  Google Scholar 

  45. Silverman SL. The clinical consequences of vertebral compression fracture. Bone. 1992;13(2):S27–31.

    Article  PubMed  Google Scholar 

  46. Lyles KW. Management of patients with vertebral compression fractures. Pharmacotherapy. 1999;19:21S–4S.

    Article  CAS  PubMed  Google Scholar 

  47. Cherasse A, Muller G, Ornetti P. Tolerability of opioids in patients with acute pain due to nonmalignant musculoskeletal disease. A hospital-based observational study. Joint Bone Spine. 2004;71:572–6.

    Article  PubMed  Google Scholar 

  48. Browning R, Jackson JL, O’Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001;161:1613–20.

    Article  CAS  PubMed  Google Scholar 

  49. Knopp JA, Diner BM, Blitz M. Calcitonin for treating acute back pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int. 2005;16:1281–90.

    Article  CAS  PubMed  Google Scholar 

  50. Prather H, Watson JO, Gilula LA. Nonoperative management of osteoporotic vertebral compression fractures. Injury. 2007;38(S3):S40–8.

    Article  PubMed  Google Scholar 

  51. Kim DH, Vaccaro AR. Osteoporotic compression fractures of the spine; current options and considerations for treatment. Spine J. 2006;6:479–87.

    Article  PubMed  Google Scholar 

  52. Sinaki M, Itoi E, Wahner HW. Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women. Bone. 2002;30:836–41.

    Article  CAS  PubMed  Google Scholar 

  53. Sinaki M, Lynn SG. Reducing the risk of falls through proprioceptive dynamic posture training in osteoporotic women with kyphotic posturing: a randomized pilot study. Am J Phys Med Rehabil. 2002;81:241–6.

    Article  PubMed  Google Scholar 

  54. Sinaki M, Brey RH, Hughes CA. Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. Mayo Clin Proc. 2005;80:849–55.

    Article  PubMed  Google Scholar 

  55. Itoi E, Sinaki M. Effect of back-strengthening exercise on posture in healthy women 49 to 65 years of age. Mayo Clin Proc. 1994;69:1054–9.

    Article  CAS  PubMed  Google Scholar 

  56. Bennell KL, Matthews B, Greig A. Effects of an exercise and manual therapy program on physical impairments, function and quality-of-life in people with osteoporotic vertebral fracture: a randomized, single-blind controlled pilot trial. BMC Musculoskelet Disord. 2010;11:36.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med. 2007;146:839–47.

    Article  PubMed  Google Scholar 

  58. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. NEJM. 1998;339(5):292–9.

    Article  CAS  PubMed  Google Scholar 

  59. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–41.

    Article  CAS  PubMed  Google Scholar 

  60. Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91.

    Article  CAS  PubMed  Google Scholar 

  61. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11(4):331–7.

    Article  CAS  PubMed  Google Scholar 

  62. Black DM, Delmas PD, Eastell R, Horizon Pivotal Fracture Trial, et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):189–1822.

    Article  Google Scholar 

  63. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37.

    Article  PubMed  Google Scholar 

  64. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118–24.

    Article  CAS  PubMed  Google Scholar 

  65. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–82.

    Article  CAS  PubMed  Google Scholar 

  66. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–52.

    Article  CAS  PubMed  Google Scholar 

  67. Chestnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(18):1241–9.

    Article  CAS  Google Scholar 

  68. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809.

    Article  CAS  PubMed  Google Scholar 

  69. U.S. Food and Drug Administration. Reclast (zoledronic acid): drug safety communication- new contraindication and updated warning on kidney impairment. Posted 09/01/2011. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270464.htm.

  70. Khosla S, Burr D, Abrahmsen B, American Society for Bone and Mineral Research, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1470–91.

    Article  Google Scholar 

  71. Shane E, Burr D, Abrahmsen B, American Society for Bone and Mineral Research, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.

    Article  PubMed  Google Scholar 

  72. Adler RA, El-Haji FG, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R, Pignolo RJ, Sellmeyer DE. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16–35.

    Article  CAS  PubMed  Google Scholar 

  73. Lacey DL, Timms E, Tan HI, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.

    Article  CAS  PubMed  Google Scholar 

  74. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(19):1914.

    CAS  Google Scholar 

  75. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: a systemic review and position statement by ECTS. Bone. 2017;105:11–7.

    Article  PubMed  Google Scholar 

  76. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45. (Erratum in: N Engl J Med 2009;282(22):2124.)

    Article  CAS  PubMed  Google Scholar 

  77. Saag K, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–39.

    Article  CAS  PubMed  Google Scholar 

  78. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu M-Y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33.

    Article  CAS  PubMed  Google Scholar 

  79. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.

    Article  CAS  PubMed  Google Scholar 

  80. Lim SY, Bolster MB. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther. 2017;11:1221–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43.

    Article  CAS  PubMed  Google Scholar 

  82. Boonen S, Ferrari S, Miller PD. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk- a perspective. J Bone Miner Res. 2012;27(5):963–74.

    Article  CAS  PubMed  Google Scholar 

  83. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis- for whom and for how long? N Engl J Med. 2012;366(22):2051–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.

    Article  CAS  PubMed  Google Scholar 

  85. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA

    Faye N. Hant

  2. Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Marcy B. Bolster

Authors
  1. Faye N. Hant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcy B. Bolster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faye N. Hant .

Editor information

Editors and Affiliations

  1. Vice Chair and Residency Program Director, Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA

    Afshin E. Razi

  2. Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Stuart H. Hershman

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hant, F.N., Bolster, M.B. (2020). Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture. In: Razi, A., Hershman, S. (eds) Vertebral Compression Fractures in Osteoporotic and Pathologic Bone. Springer, Cham. https://doi.org/10.1007/978-3-030-33861-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-33861-9_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-33860-2

  • Online ISBN: 978-3-030-33861-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation